We observed that biochemical non-responders (who comprised of patients who did not attain an undetectable PSA post-RT or had a PSA relapse) harboured PCa with a lower AR activity than responders, which was consistent with previous findings showing a negative association between AR activity and response to enzalutamide [28]. The gene discussed is AR; the disease is posterior cortical atrophy.